{"id":3070,"date":"2023-05-06T00:56:18","date_gmt":"2023-05-06T04:56:18","guid":{"rendered":"https:\/\/bnderm.com\/main\/?page_id=3070"},"modified":"2025-10-16T09:32:56","modified_gmt":"2025-10-16T13:32:56","slug":"clinical-trials","status":"publish","type":"page","link":"https:\/\/bnderm.com\/main\/clinical-trials\/","title":{"rendered":"Clinical Trials"},"content":{"rendered":"<p><b>Currently Recruiting Studies<\/b><\/p>\n<p><b>If you are interested in finding out more details about our ongoing studies, contact us at 416-222-2204 or by email at <\/b><b>trials@bnderm.com<\/b><span style=\"font-weight: 400;\">.<\/span><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A Study to Evaluate the Efficacy and Safety of Subcutaneous <\/span><b>Sonelokimab<\/b><span style=\"font-weight: 400;\"> Compared With Placebo in Adult Participants with Moderate to Severe Hidradenitis Suppurativa <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06411899?locStr=Toronto,%20ON,%20Canada&amp;country=Canada&amp;state=Ontario&amp;city=Toronto&amp;cond=Hidradenitis%20Suppurativa&amp;intr=Sonelokimab&amp;rank=2\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With <\/span><b>Dupilumab<\/b><span style=\"font-weight: 400;\"> Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2) <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06687980?term=efc18366&amp;rank=1\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">An observational study to learn about the effects of a Triple Combination gel treatment that contains <\/span><b>Clindamycin<\/b> <b>Phosphate<\/b><span style=\"font-weight: 400;\">, <\/span><b>Adapalene<\/b><span style=\"font-weight: 400;\">, and <\/span><b>Benzoyl<\/b> <b>Peroxide<\/b><span style=\"font-weight: 400;\"> in Canadian Patients With Acne Vulgaris (CHARM) <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07205107?term=physio%20OR%20physical%20therapy%20OR%20exercise%20therapy%20OR%20physiotherapy\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Real World Study to Assess Change in Quality of Life of <\/span><b>Risankizumab<\/b><span style=\"font-weight: 400;\"> Treatment in Adult Participants With Moderate-to-Severe Plaque Psoriasis <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07039110\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A Study to See How Well <\/span><b>Lebrikizumab<\/b><span style=\"font-weight: 400;\"> Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden (ADsolve)<\/span> <a href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT07006792\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A Study to Evaluate the Efficacy and Safety Study of <\/span><b>Povorcitinib<\/b><span style=\"font-weight: 400;\"> in Participants With Prurigo Nodularis (STOP-PN1) <\/span><a href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT06516952?cond=Prurigo%20Nodularis&amp;term=INCB054707&amp;rank=3\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Long-Term Safety Study of <\/span><b>Deucravacitinib<\/b><span style=\"font-weight: 400;\"> Versus <\/span><b>Ustekinumab<\/b><span style=\"font-weight: 400;\"> in Participants With Psoriasis (PRAGMATYK) <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT07116967\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">An Interventional study is to learn if <\/span><b>TRIV-509<\/b><span style=\"font-weight: 400;\"> works to treat Moderate to Severe Atopic Dermatitis in Adults <\/span><a href=\"https:\/\/www.clinicaltrials.gov\/study\/NCT07167758\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of <\/span><b>Barzolvolimab<\/b><span style=\"font-weight: 400;\"> (CDX-0159) in Patients With Prurigo Nodularis<\/span> <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06366750?locStr=Toronto,%20ON,%20Canada&amp;country=Canada&amp;state=Ontario&amp;city=Toronto&amp;cond=Prurigo%20Nodularis&amp;intr=barzolvolimab&amp;rank=1\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of <\/span><b>Barzolvolimab<\/b><span style=\"font-weight: 400;\"> in Patients With Chronic Spontaneous Urticaria Who Remain Symptomatic Despite H1 Antihistamine Treatment (EMBARQ-CSU2) <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06455202?intr=barzolvolimab&amp;rank=2\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<\/ul>\n<p><b>No Longer Recruiting<\/b><\/p>\n<ul>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A Study to Investigate Vaccine Responses in Subcutaneous <\/span><b>Amlitelimab<\/b><span style=\"font-weight: 400;\"> Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo (HYDRO) <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06015308\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Real-World Effectiveness of <\/span><b>Dupilumab<\/b><span style=\"font-weight: 400;\"> in Patients With Prurigo Nodularis: An Observational Study (GLOBOSPIN) <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05991323?locStr=Toronto,%20ON,%20Canada&amp;country=Canada&amp;state=Ontario&amp;city=Toronto&amp;cond=Prurigo%20Nodularis&amp;intr=Dupilumab&amp;rank=1\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A phase 3 randomized, double-blind, 52-week placebo-controlled multi-center study with a double-blind 52-week extension period with randomized dose up\/dose down titration investigating the efficacy, safety, and tolerability of <\/span><b>Ritlecitinib<\/b><span style=\"font-weight: 400;\"> in adult participants with nonsegmental vitiligo <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06072183?locStr=Toronto,%20ON,%20Canada&amp;country=Canada&amp;state=Ontario&amp;city=Toronto&amp;cond=Vitiligo&amp;intr=ritlecitinib&amp;rank=2\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A Study to Evaluate the Efficacy and Safety of <\/span><b>ESK-001<\/b><span style=\"font-weight: 400;\"> in Patients with Moderate to Severe Plaque Psoriasis (ONWARD1) <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06586112?locStr=Toronto,%20ON,%20Canada&amp;country=Canada&amp;state=Ontario&amp;city=Toronto&amp;cond=Psoriasis&amp;intr=ESK-001&amp;rank=3\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A Phase 3, Multicenter, Open-Label Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of <\/span><b>TAK-279<\/b><span style=\"font-weight: 400;\"> in Subjects With Moderate-to-Severe Plaque Psoriasis <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06550076?locStr=Toronto,%20ON,%20Canada&amp;country=Canada&amp;state=Ontario&amp;city=Toronto&amp;cond=Psoriasis&amp;intr=TAK-279&amp;rank=1\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A Study About How Well <\/span><b>TAK-279<\/b><span style=\"font-weight: 400;\"> Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment<\/span> <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06088043\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A Study to Evaluate Efficacy and Safety of <\/span><b>Povorcitinib<\/b><span style=\"font-weight: 400;\"> in Participants With Nonsegmental Vitiligo (STOP-V1) <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT06113445?cond=NonSegmental%20Vitiligo&amp;intr=povorcitinib&amp;rank=2\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A Study to Evaluate the Efficacy and Safety of <\/span><b>Ruxolitinib<\/b><span style=\"font-weight: 400;\"> Cream in Participants With Prurigo Nodularis (PN) (TRuE-PN2) <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05764161?cond=Prurigo%20Nodularis&amp;intr=Ruxolitinib%20cream&amp;aggFilters=phase:3,status:not%20rec&amp;rank=1\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Study of <\/span><b>Daxdilimab<\/b><span style=\"font-weight: 400;\"> (HZN-7734) in Patients With Moderate-to-Severe Primary Discoid Lupus Erythematosus<\/span> <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05591222\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A Study to Assess Real-World Use, Safety, and Effectiveness of Oral <\/span><b>Upadacitinib<\/b><span style=\"font-weight: 400;\"> in Adult and Adolescent (&gt;=12 Years Old) Participants With Atopic Dermatitis (AD-VISE) <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05081557\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A Study Assessing <\/span><b>Rocatinlimab<\/b><span style=\"font-weight: 400;\"> in Combination With Topical Corticosteroid and\/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-SHUTTLE) <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05724199\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Canadian Real World Evidence Study of <\/span><b>Brodalumab<\/b><span style=\"font-weight: 400;\"> in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity (CARE) <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05132231\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A 52-Week Study of <\/span><b>Ritlecitinib<\/b><span style=\"font-weight: 400;\"> Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo (Tranquillo) <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05583526\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A 24 Week Trial to Compare the Efficacy and Safety of <\/span><b>Delgocitinib<\/b><span style=\"font-weight: 400;\"> Cream 20 mg\/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05259722\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Efficacy and Safety of Delgocitinib Cream in Adults With Moderate to Severe Chronic Hand Eczema (DELTA 2) <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04872101\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Study to Evaluate the Efficacy and Safety of <\/span><b>INCB054707<\/b><span style=\"font-weight: 400;\"> in Participants With Vitiligo <\/span><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04818346\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A Study to Investigate Interchangeability of <\/span><b>ABP 654<\/b><span style=\"font-weight: 400;\"> for the Treatment of Participants With Moderate to Severe Plaque Psoriasis <\/span><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04761627\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of <\/span><b>Nemolizumab<\/b><span style=\"font-weight: 400;\"> (CD14152) in Subjects with Prurigo Nodularis <\/span><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04501679\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A Randomized, Double-Blind and Placebo-Controlled Phase 3 Study to Evaluate Efficacy and Safety of Oral SHR0302 in Subjects Aged 12 Years and Older with Moderate to Severe Atopic Dermatitis <\/span><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04875169\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A Study to Evaluate the Efficacy and Safety of <\/span><b>Bimekizumab<\/b><span style=\"font-weight: 400;\"> in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE BRIGHT) <\/span><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03598790\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">A Study to Evaluate <\/span><b>Upadacitinib<\/b><span style=\"font-weight: 400;\"> in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis (Measure Up 2) <\/span><a href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03607422\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Study to Evaluate Efficacy and Safety of <\/span><b>PF-04965842<\/b><span style=\"font-weight: 400;\"> With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis (JADE EXTEND) <\/span><a href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT03422822\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis (VALUE) <\/span><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03982394\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Evaluation of the Efficacy and Safety of <\/span><b>Lebrikizumab<\/b><span style=\"font-weight: 400;\"> (LY3650150) in Moderate to Severe Atopic Dermatitis (ADvocate2) <\/span><a href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04178967\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Long-Term Safety and Efficacy of <\/span><b>BMS-986165<\/b><span style=\"font-weight: 400;\"> in Subjects with Psoriasis <\/span><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04036435\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<li style=\"font-weight: 400;\" aria-level=\"1\"><span style=\"font-weight: 400;\">Open-Label Extension Study of <\/span><b>Upadacitinib<\/b><span style=\"font-weight: 400;\"> in Adult Participants With Moderate to Severe Atopic Dermatitis <\/span><a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04195698\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/li>\n<\/ul>\n<p><span style=\"font-weight: 400;\">A Registry of Patients With Moderate to Severe Plaque Psoriasis (PURE)<\/span> <a href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02786186\"><span style=\"font-weight: 400;\">View More<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Currently Recruiting Studies If you are interested in finding out more details about our ongoing studies, contact us at 416-222-2204 or by email at trials@bnderm.com. A Study to Evaluate the Efficacy and Safety of Subcutaneous Sonelokimab Compared With Placebo in Adult Participants with Moderate to Severe Hidradenitis Suppurativa View More A Study to Investigate Improvement [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":6,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"_links":{"self":[{"href":"https:\/\/bnderm.com\/main\/wp-json\/wp\/v2\/pages\/3070"}],"collection":[{"href":"https:\/\/bnderm.com\/main\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/bnderm.com\/main\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/bnderm.com\/main\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/bnderm.com\/main\/wp-json\/wp\/v2\/comments?post=3070"}],"version-history":[{"count":26,"href":"https:\/\/bnderm.com\/main\/wp-json\/wp\/v2\/pages\/3070\/revisions"}],"predecessor-version":[{"id":4151,"href":"https:\/\/bnderm.com\/main\/wp-json\/wp\/v2\/pages\/3070\/revisions\/4151"}],"wp:attachment":[{"href":"https:\/\/bnderm.com\/main\/wp-json\/wp\/v2\/media?parent=3070"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}